Sign In
Buy GKOS
$113.64
+2.86 (+2.58%)
At Close: Jun 03, 2026
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
07:00am, Wednesday, 09'th Jul 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
04:05pm, Wednesday, 25'th Jun 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
07:00am, Wednesday, 25'th Jun 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
What Makes Glaukos (GKOS) a New Buy Stock
01:01pm, Monday, 16'th Jun 2025
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Glaukos (GKOS) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
11:00am, Wednesday, 11'th Jun 2025
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Here's Why You Should Retain Glaukos Stock in Your Portfolio
08:20am, Wednesday, 21'st May 2025
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
01:01pm, Thursday, 01'st May 2025
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
12:35pm, Thursday, 01'st May 2025
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript
10:05pm, Wednesday, 30'th Apr 2025
Glaukos Corporation (NYSE:GKOS ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Chris Lewis - Vice President of Investor Relations and Corporate Affairs Tom Burns - Ch
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
06:30pm, Wednesday, 30'th Apr 2025
Glaukos (GKOS) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.70 per share a year ago.
Glaukos Announces First Quarter 2025 Financial Results
04:05pm, Wednesday, 30'th Apr 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
11:30am, Tuesday, 29'th Apr 2025
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Wednesday, 23'rd Apr 2025
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
07:00am, Wednesday, 23'rd Apr 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Announces the Release of its 2024 Sustainability Report
07:00am, Wednesday, 16'th Apr 2025
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
